EPINEPHRINE, [68Ga]Ga-PentixaFor, -, PARACETAMOL, FLUDEOXYGLUCOSE (18F), - clinical trials

Exploratory study evaluating the relevance of [68Ga]Ga-PentixaFor for initial staging and detection of minimal residual disease in multiple myeloma patients eligible for autologous stem cell transplantation less than 66 years included in the prospective IFM 2020-02.

This study looks at a new type of scan, called [68Ga]Ga-PentixaFor, for people under 66 with multiple myeloma. It checks how well this scan finds the cancer when first diagnosed and helps track if any cancer cells remain after treatment.